Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA
Maren Hermanns‐Clausen, Dieter Müller, Josephine Kithinji, et al.
Clinical Toxicology (2017) Vol. 56, Iss. 6, pp. 404-411
Closed Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists
Arianna Giorgetti, Francesco Paolo Busardò, Roberta Tittarelli, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 104
Synthetic cannabinoid receptor agonists: classification and nomenclature
Adam Potts, Céline Cano, Simon H. L. Thomas, et al.
Clinical Toxicology (2019) Vol. 58, Iss. 2, pp. 82-98
Closed Access | Times Cited: 91
Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists
Elise Wouters, Jolien Walraed, Samuel D. Banister, et al.
Biochemical Pharmacology (2019) Vol. 169, pp. 113623-113623
Closed Access | Times Cited: 79
Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review
M. Oliveira, Mariana Capelo Vides, Dângela Layne Silva Lassi, et al.
Brain Sciences (2023) Vol. 13, Iss. 7, pp. 990-990
Open Access | Times Cited: 32
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Daniela-Mădălina Ciucă Anghel, Gabriela Viorela Nițescu, Andreea Taisia Tiron, et al.
Molecules (2023) Vol. 28, Iss. 13, pp. 4969-4969
Open Access | Times Cited: 28
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery
Lei Tian, Taotao Qiang, Shanglong Liu, et al.
Pharmacology & Therapeutics (2025), pp. 108795-108795
Closed Access | Times Cited: 1
The relationship between cannabis and cardiovascular disease: clearing the haze
Mark Chandy, Nerea Jimenez-Tellez, Joseph C. Wu
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 1
Review of the many faces of synthetic cannabinoid toxicities
Azita Alipour, Puja Patel, Zaheera Shabbir, et al.
Mental Health Clinician (2019) Vol. 9, Iss. 2, pp. 93-99
Open Access | Times Cited: 64
What are the psychological effects of using synthetic cannabinoids? A systematic review
Hina Akram, Claire Mokrysz, H. Valerie Curran
Journal of Psychopharmacology (2019) Vol. 33, Iss. 3, pp. 271-283
Open Access | Times Cited: 51
Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐tert‐leucine
Elise Wouters, Lukas Mogler, Annelies Cannaert, et al.
Drug Testing and Analysis (2019) Vol. 11, Iss. 8, pp. 1183-1191
Open Access | Times Cited: 43
Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists
Monica Patel, David B. Finlay, Michelle Glass
Cellular Signalling (2020) Vol. 78, pp. 109865-109865
Closed Access | Times Cited: 34
Cannabinoid toxicity in pediatrics
Eike Blohm, Peter J. Sell, Mark Neavyn
Current Opinion in Pediatrics (2019) Vol. 31, Iss. 2, pp. 256-261
Closed Access | Times Cited: 35
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
Richard C. Kevin, Lyndsey L. Anderson, Iain S. McGregor, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 33
Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC–MS and LC–MS-MS analysis
Abdullah Al-Matrouk, Mahasen Alqallaf, Adel AlShemmeri, et al.
Forensic Science International (2019) Vol. 303, pp. 109960-109960
Closed Access | Times Cited: 33
Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE
Arianna Giorgetti, Lukas Mogler, Sebastian Halter, et al.
Forensic Toxicology (2019) Vol. 38, Iss. 2, pp. 314-326
Open Access | Times Cited: 30
An Internet Snapshot Survey Assessing the sale of Synthetic Cannabinoid Receptor Agonists for use with Electronic Vaping Devices
Allon Gould, Paul I. Dargan, David M. Wood
Journal of Medical Toxicology (2024) Vol. 20, Iss. 3, pp. 271-277
Open Access | Times Cited: 3
Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
J S James, Jessica Thrush, Taher M Yusufali, et al.
Drug and Alcohol Dependence (2025) Vol. 272, pp. 112672-112672
Closed Access
Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists
Monica Patel, Xiaoxi Zheng, Luli R. Akinfiresoye, et al.
European Journal of Pharmacology (2024) Vol. 971, pp. 176549-176549
Open Access | Times Cited: 3
Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity
Sarah Anderson, Anna M. Oprescu, Diane P. Calello, et al.
PEDIATRICS (2019) Vol. 144, Iss. 2
Open Access | Times Cited: 24
Blood concentrations of synthetic cannabinoids
Piotr Adamowicz
Clinical Toxicology (2020) Vol. 59, Iss. 3, pp. 246-251
Closed Access | Times Cited: 21
Respiratory failure in confirmed synthetic cannabinoid overdose
Alex F. Manini, Alex J. Krotulski, Jonathan Schimmel, et al.
Clinical Toxicology (2021) Vol. 60, Iss. 4, pp. 524-526
Open Access | Times Cited: 19
Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act
Nicholas E. Webb, David M. Wood, Shaun L. Greene, et al.
Clinical Toxicology (2018) Vol. 57, Iss. 1, pp. 36-41
Closed Access | Times Cited: 21
Cumyl‐PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?
Sebastian Halter, Verena Angerer, J. Röhrich, et al.
Drug Testing and Analysis (2018) Vol. 11, Iss. 2, pp. 347-349
Closed Access | Times Cited: 21
Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro
Chris Bladen, Somayeh Mirlohi, Marina Santiago, et al.
Neuropharmacology (2021) Vol. 187, pp. 108478-108478
Open Access | Times Cited: 17
Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis
Eef L. Theunissen, Johannes T. Reckweg, Nadia R. P. W. Hutten, et al.
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1251-1261
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top